Rosé Adriana, André Nicolas, Rozados Viviana R, Mainetti Leandro E, Menacho Márquez Mauricio, Rico María José, Schaiquevich Paula, Villarroel Milena, Gregianin Lauro, Graupera Jaume Mora, García Wendy Gómez, Epelman Sidnei, Alasino Carlos, Alonso Daniel, Chantada Guillermo, Scharovsky O Graciela
Hospital de Pediatría 'JP Garrahan', Combate de los Pozos 1800, C 1245 AAM, CABA Argentina.
Inserm UMR_S 911, Centre de Recherche en Oncologie Biologique et Oncopharmacologie, 27 Boulevard Jean Moulin, Faculté de Pharmacie, Aix-Marseille Université; Service d'Hématologie & Oncologie Pédiatrique, AP‑HM, 13005 Marseille, France.
Ecancermedicalscience. 2016 Sep 6;10:672. doi: 10.3332/ecancer.2016.672. eCollection 2016.
Following previous metronomic meetings in Marseille (2011), Milano (2014), and Mumbai (2016), the first Latin American metronomic meeting was held in the School of Medical Sciences, National University of Rosario, Rosario, Argentina on 27 and 28 of May, 2016. For the first time, clinicians and researchers with experience in the field of metronomics, coming from different countries in Latin America, had the opportunity of presenting and discussing their work. The talks were organised in three main sessions related to experience in the pre-clinical, and clinical (paediatric and adult) areas. The different presentations demonstrated that the fields of metronomic chemotherapy and repurposing drugs in oncology, known as metronomics, constitute a branch of cancer therapy in permanent evolution, which have strong groups working in Latin America, both in the preclinical and the clinical settings including large, adequately designed randomised studies. It was shown that metronomics offers treatments, which, whether they are combined or not with the standard therapeutic approaches, are not only effective but also minimally toxic, with the consequent improvement of the patient's quality of life, and inexpensive, a feature very important in low resource clinical settings. The potential use of metronomic chemotherapy was proposed as a cost/effective treatment in low-/middle-income countries, for adjuvant therapy in selected tumours. The fundamental role of the governmental agencies and non-governmental alliances, as the Metronomic Global Health Initiative, in supporting this research with public interest was underlined.
继此前分别于2011年在马赛、2014年在米兰以及2016年在孟买召开的节拍化疗会议之后,首届拉丁美洲节拍化疗会议于2016年5月27日至28日在阿根廷罗萨里奥国立大学医学科学院举行。来自拉丁美洲不同国家、在节拍化疗领域富有经验的临床医生和研究人员首次有机会展示并讨论他们的工作。会议讨论分为三个主要环节,分别涉及临床前领域以及临床(儿科和成人)领域的经验。不同的发言表明,节拍化疗以及肿瘤学中药物重新利用领域,即所谓的节拍化疗,构成了一个不断发展的癌症治疗分支,在拉丁美洲,无论是临床前还是临床环境中,都有强大的团队在开展工作,包括大型、设计充分的随机研究。结果表明,节拍化疗所提供的治疗方法,无论是否与标准治疗方法联合使用,不仅有效,而且毒性极小,从而改善了患者的生活质量,并且成本低廉,这在资源匮乏的临床环境中是一个非常重要的特点。节拍化疗被提议作为中低收入国家针对特定肿瘤辅助治疗的一种具有成本效益的治疗方法。会议强调了政府机构和非政府联盟(如全球节拍化疗健康倡议)在支持这项具有公共利益的研究方面的重要作用。